CSL (CSL.AX) Cổ phiếu Giá

CSL Ltd is primarily active in the biotechnology and pharmaceutical industries.

The main competitors of CSL Ltd in the market are Biogen Inc., Grifols S.A., and Shire Plc.

CSL Ltd, also known as CSL Limited, is a global biotechnology company headquartered in Australia. Established in 1916, CSL has a rich history of over a century. Originally known as the Commonwealth Serum Laboratories, it transitioned into a private company in 1994. CSL specializes in the research, development, manufacturing, and marketing of innovative biotherapies and vaccines to combat serious medical conditions. With a strong commitment to improving public health, CSL has expanded its operations globally and has become a trusted name in the biopharmaceutical industry. Today, CSL Ltd continues to make significant contributions to healthcare worldwide through its advanced technologies and dedicated team.

CSL Ltd, a renowned Australian biotechnology company, has achieved numerous significant milestones throughout its history. Notably, CSL Ltd successfully developed and marketed first-of-its-kind blood plasma products and vaccines. They introduced the world's first recombinant product derived from human genes, being pivotal in the treatment of hemophilia. CSL Ltd has also made groundbreaking advancements in the field of immunoglobulins, leading to innovative therapies. Furthermore, the company expanded its global presence and became a major player in the biopharmaceutical industry. With its dedication to research, development, and revolutionizing healthcare, CSL Ltd continues to make remarkable contributions to the medical field.

CSL Ltd is primarily present in various countries and regions across the globe. These include Australia, the company's home country where it is headquartered, North America, Europe, and Asia-Pacific. With a strong global presence, CSL Ltd has established itself as a leading biotechnology company, providing innovative and life-saving solutions in the areas of vaccines, plasma therapies, and recombinant products. As a multinational corporation, CSL Ltd has successfully expanded its operations and collaborations internationally, further strengthening its position in the global market.

CSL Ltd represents strong values and a dedicated corporate philosophy. As a global biotechnology company, CSL is committed to enhancing the health and well-being of people worldwide. The company strives for excellence in its operations, focusing on innovation, quality, and patient-centric outcomes. CSL upholds integrity, ethics, and transparency in all aspects of its business, fostering trust with stakeholders. With a mission to save lives and improve patient outcomes, CSL maintains a customer-driven approach, continuously working towards breakthroughs in medical research and development. Through its commitment to these values and corporate philosophy, CSL Ltd demonstrates its dedication to making a positive impact on global healthcare.

Các nhà phân tích hiện đặt giá mục tiêu trung bình 150,96 USD cho cổ phiếu CSL (trung vị: 141,84 USD), tức +9,5 % so với giá mới nhất. Đồng thuận dựa trên 20 xếp hạng.

CSL Mục Tiêu Giá Của Nhà Phân Tích 2026

20 nhà phân tích hiện xếp hạng cổ phiếu CSL: 13 khuyến nghị mua, 7 nắm giữ và 0 bán.

CSL Mục Tiêu Giá Của Nhà Phân Tích 2026

Quy đổi theo tỷ giá hiện tại, cổ phiếu CSL giao dịch ở mức 123,05 EUR (137,88 USD).

Cổ phiếu CSL (CSL.AX) niêm yết tại 7 sở giao dịch, gồm: SIX (Zürich) (CSL.SW), ASX (CSL.AX), Frankfurt (CSJ.F), München (CSJ.MU), Düsseldorf (CSJ.DU), Hamburg (CSJ.HM).

CSL is a global biotechnology company focused on the production of plasma and vaccine products. The company is divided into two divisions: CSL Behring and Seqirus. CSL Behring produces plasma derivatives used to treat life-threatening diseases and disorders such as Alpha-1 antitrypsin deficiency, bleeding disorders, and immune deficiencies. CSL Behring is the third largest producer of plasma derivatives worldwide with production facilities on five continents. Seqirus is the vaccine division of CSL and focuses on the research, development, manufacturing, and marketing of influenza vaccines. The company is the second largest producer of influenza vaccines globally and has production facilities worldwide. Additionally, CSL also produces products in the field of immunosuppression and inflammatory diseases. The company prides itself on meeting some of the highest quality standards in the industry and collaborate closely with patient organizations to promote understanding of the importance of plasma derivatives and vaccines. CSL's business model is based on the research, development, and production of biological products to treat and prevent life-threatening diseases and disorders. CSL's plasma derivatives and vaccines are often life-saving and essential for the health and lives of many people. CSL invests significantly in research and development to develop and improve new products and treatments. The company works closely with government agencies and health organizations to ensure that its products meet the highest standards and are accessible worldwide. To further strengthen its business model, CSL has developed a long-term growth strategy based on innovation, capacity expansion, and geographic expansion. The company will continue to invest in new technologies and research and development to meet the growing demand for life-saving products and treatments. In summary, CSL is a global biotechnology company focused on the production of plasma derivatives and vaccines. The company has two main divisions, CSL Behring and Seqirus, and also produces products in the field of immunosuppression and inflammatory diseases. The business model is based on research, development, and production of biological products to treat and prevent life-threatening diseases and disorders. The company invests significantly in research and development to develop and improve new products and treatments and has developed a long-term growth strategy to meet the growing demand for life-saving products and treatments.

Doanh thu của CSL là 16,04 tỷ USD. Con số này dựa trên dữ liệu tài chính hiện tại và phản ánh hiệu suất kinh doanh của công ty.

Lợi nhuận của CSL là -2,64 tỷ USD. Lợi nhuận ròng phản ánh khả năng sinh lợi của công ty sau khi khấu trừ tất cả các chi phí.

Tỷ lệ giá trên lợi nhuận (P/E) của CSL hiện tại là -25,05. Tỷ lệ P/E so sánh giá cổ phiếu hiện tại với lợi nhuận trên mỗi cổ phiếu và giúp nhà đầu tư đánh giá định giá của cổ phiếu CSL.

Tỷ lệ giá trên doanh số bán hàng (P/S) của CSL hiện tại là 4,12. Tỷ lệ P/S so sánh vốn hóa thị trường với doanh thu hàng năm và dùng làm chỉ số định giá của cổ phiếu CSL.

Điểm chất lượng AlleAktien cho CSL là 7/10.

ISIN của CSL là AU000000CSL8. ISIN (International Securities Identification Number) là một mã định danh duy nhất trên toàn cầu cho các chứng chỉ.

WKN của CSL là 890952. WKN (Wertpapierkennnummer) là một mã nhận dạng chứng chỉ Đức gồm sáu chữ số.

Ticker của CSL là CSL.AX. Ký hiệu ticker được sử dụng để giao dịch cổ phiếu CSL trên sàn chứng chỉ.